US Market News
3月前
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsMarch 9, 2026 10:50 AM
PR Newswire (US)
Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /PRNewswire/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ: HELP), Compass Pathways (NASDAQ: CMPS), AtaiBeckley (NASDAQ: ATAI), Definium Therapeutics (NASDAQ: DFTX), and GH Research (NASDAQ: GHRS). The World Health Organization estimates that depression and anxiety cost the global economy more than $1 trillion annually in lost productivity3. Treatment-resistant depression alone affects roughly 30% of patients diagnosed with major depressive disorder, fueling demand for novel mechanisms that can deliver rapid, durable therapeutic responses where traditional antidepressants have failed4. The pipeline is moving to meet it, and pharmaceutical capital is following.Helus Pharma™ (NASDAQ: HELP) is a clinical-stage pharmaceutical company developing novel serotonergic agonists for serious mental health conditions, including major depressive disorder and generalized anxiety disorder.Helus announced topline results from a Phase 2 signal detection study evaluating HLP004 as a potential adjunctive treatment for adults with moderate-to-severe generalized anxiety disorder who remained symptomatic despite ongoing standard-of-care antidepressant therapy. GAD affects more than 20 million adults in the United States, and no adjunctive pharmacologic treatment for the condition has ever been approved.In the study, 36 patients were randomized to HLP004 20 mg or 2 mg and received two intramuscular doses three weeks apart. Patients receiving 20 mg adjunctive to standard of care achieved a mean HAM-A reduction of 10.4 points (p
MomsSpaghetti
3月前
ATAI Exploring $2B+ Deal for Psychedelic Depression Drug (Bloomberg Summary + Context)
A new Bloomberg report says **Atai Life Sciences’ joint venture AtaiBeckley is exploring strategic options for its lead psychedelic depression therapy BPL-003, including a sale or large pharmaceutical partnership potentially valued at $2B+.
According to people familiar with the discussions, the company has hired Jefferies Financial Group and JPMorgan Chase to run the process and approach potential pharma partners. The drug recently received FDA clearance to enter Phase 3 clinical trials for treatment-resistant depression.
https://www.bloomberg.com/news/articles/2026-03-07/ataibeckley-is-said-to-explore-options-for-main-psychedelic-drug?leadSource=reddit_wall
Some key details from the report:
BPL-003 is a nasal spray psychedelic therapy designed for rapid treatment of severe depression.
Over 20 million adults in the U.S. suffer from major depression, and roughly 30% don’t respond to existing treatments.
A deal could include co-development, where a large pharma partner helps fund Phase 3 trials and commercialization in exchange for revenue sharing.
Other options include royalty licensing or an outright asset sale.
The article notes that large pharma interest in psychedelic-style antidepressants has grown significantly since **Johnson & Johnson turned its ketamine-based drug Spravato into a multi-billion-dollar treatment for resistant depression.
Importantly, ATAI’s entire market cap is currently around $1.2B, meaning the company is reportedly seeking a partnership value greater than its current valuation for just one drug asset.
Why Partnerships Like This Matter for Small Biotech Stocks
In biotech, a large pharma partnership can completely change a company’s trajectory. These deals typically:
Fund expensive Phase 3 trials
Validate the science in the eyes of investors
Reduce dilution risk
Provide global commercialization capabilities
Because of this, biotech stocks sometimes reprice dramatically after partnerships or licensing deals.
Examples of Small Biotech Companies That Exploded After Partnerships
Here are several well-known examples where major partnerships helped trigger massive stock moves.
BioNTech
Before COVID vaccines existed, **BioNTech signed major collaborations with big pharma including Pfizer and Bristol Myers Squibb.
Stock performance:
2019 IPO price: about $13
2021 peak: about $400
➡ roughly 30× return
Large pharma partnerships helped validate the company’s mRNA platform technology long before the vaccine success.
Arrowhead Pharmaceuticals
RNA drug developer **Arrowhead Pharmaceuticals signed a major licensing agreement with Novartis worth up to $2B in milestones.
Stock performance:
2016: around $2–3
2021 peak: roughly $90
➡ about 30×
The partnership signaled that RNA interference drugs were commercially viable.
Exelixis
Cancer drug developer **Exelixis partnered with Bristol Myers Squibb and others to develop its drug cabozantinib.
Stock performance:
2012: roughly $1–2
2018 peak: around $30
➡ roughly 15×
Partnership funding helped the company finish development and bring a blockbuster cancer drug to market.
Moderna
Before its COVID vaccine success, **Moderna signed multi-billion-dollar research partnerships with Merck & Co. and AstraZeneca.
Stock performance:
2018 IPO: about $23
2021 peak: about $450
➡ roughly 20×
The partnerships validated the mRNA therapeutic platform years before commercialization.
Why This Could Be Important for Psychedelic Biotech
If a major pharmaceutical company partners with ATAI on BPL-003, it would likely signal that psychedelic-derived treatments for depression are entering mainstream pharma development.
That kind of validation could affect not just ATAI but the entire psychedelic biotech sector, especially companies working on:
treatment-resistant depression
rapid-acting antidepressants
next-generation psychedelic compounds
Bottom Line
The Bloomberg report suggests big pharma interest may be emerging around ATAI’s lead psychedelic depression drug.
If the company secures a major partnership near the $2B level, it would represent:
validation of the therapy
funding for Phase 3 trials
potential repricing of ATAI relative to its current market cap.
For investors in early-stage biotech — especially psychedelic drug developers — deals like this can sometimes become major inflection points for long-term stock performance.
US Market News
4月前
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsFebruary 27, 2026 11:44 AM
PR Newswire (US)
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ: HELP), AtaiBeckley (NASDAQ: ATAI), Definium Therapeutics (NASDAQ: DFTX), GH Research (NASDAQ: GHRS), and LB Pharmaceuticals (NASDAQ: LBRX).
A consensus statement from the U.S. National Network of Depression Centers published in The Lancet outlined considerations for integrating psychedelic into routine clinical practice, a signal that academic medicine is preparing for what the trials may deliver[3]. The clinical infrastructure is expanding, and the investment thesis is following.Helus Pharma (NASDAQ: HELP) is a clinical-stage pharmaceutical company developing treatments for depression and anxiety. Its approach centers on novel serotonergic agonists, synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity.Originally founded as Cybin in 2019, the company rebranded to Helus Pharma in January 2026, pronounced "Heal-Us," and began trading on the NASDAQ under the ticker HELP. The name reflects its transition toward a commercial-ready pharmaceutical operation.The company holds over 350 filed patents with more than 100 already granted, providing protection around its lead programs through at least 2041. It operates across Canada, the United States, the United Kingdom, and Ireland.Recently, Nature Medicine published results from a randomized, placebo-controlled Phase 2a trial of SPL026 in patients with moderate-to-severe major depressive disorder. The study enrolled 34 participants across three clinical sites in the United Kingdom.The study met its primary endpoint. Participants receiving a single 21.5 mg dose showed a mean MADRS difference of -7.35 versus placebo (p=0.023), with effects appearing within one week (p=0.002).Response rates at two weeks reached 35% versus 12% for placebo. Remission rates were 29% versus 12%.Effects were sustained for up to three months, with some participants maintaining improvements for up to six months. No treatment-related serious adverse events were reported."The findings provide clinical proof-of-concept for short-acting serotonergic modulation and further support our conviction that our novel serotonergic agonist molecules, such as HLP004, can potentially deliver meaningful outcomes with greater consistency and commercial feasibility," said Michael Cola, CEO of Helus Pharma.HLP004, a proprietary intramuscular compound informed by the SPL026 clinical insights, is now in Phase 2 for generalized anxiety disorder. Helus expects topline data from that study this quarter.The company's lead asset HLP003, a proprietary oral compound granted FDA Breakthrough Therapy Designation, is advancing through two pivotal Phase 3 studies for the adjunctive treatment of major depressive disorder.Phase 2 data on HLP003 demonstrated 100% response rates and 71% remission at 12 months after just two 16 mg doses, with an approximately 23-point reduction in MADRS scores.The APPROACH pivotal Phase 3 study has topline data anticipated in Q4 2026, while the complementary EMBRACE Phase 3 study and EXTEND long-term extension study continue to progress.Helus reported US$195.1 million in cash as of December 31, 2025, supporting continued advancement across its multi-asset clinical pipeline.CONTINUED… Read this and more news for Helus Pharma at:https://equity-insider.com/2026/02/24/this-fda-breakthrough-depression-drug-just-hit-nature-medicine-wall-street-says-its-worth-22-share/In other industry developments:AtaiBeckley (NASDAQ: ATAI) in January outlined its 2026 pipeline strategy ahead of the J.P. Morgan Healthcare Conference, reporting that its lead candidate BPL-003, a mebufotenin benzoate nasal spray for treatment-resistant depression, met its primary and all key secondary endpoints in Phase 2b. The company expects Phase 3 guidance in the first quarter and trial initiation by mid-year, with financial resources supporting operations into 2029."Following the strategic combination of atai Life Sciences and Beckley Psytech completed last year and the recent corporate redomiciliation to the United States, we enter 2026 with meaningful momentum and a clear vision for the impact AtaiBeckley can deliver for people living with difficult-to-treat mental health conditions," said Dr. Srinivas Rao, Co-Founder and CEO of AtaiBeckley.The company's broader pipeline includes VLS-01, a DMT buccal film for treatment-resistant depression with Phase 2 data expected in the second half of 2026, and EMP-01, an oral R-MDMA compound for social anxiety disorder with Phase 2a results anticipated this quarter. AtaiBeckley was added to the NASDAQ Biotechnology Index in December following its formation through the merger of atai Life Sciences and Beckley Psytech. A new patent granted in December covering its R-MDMA compound extends exclusivity through 2043.Definium Therapeutics (NASDAQ: DFTX) in January completed its rebrand from MindMed, signaling its transition from a psychedelic research platform to a late-stage psychiatry company. Its lead candidate DT120, an LSD-derived orally disintegrating tablet with FDA Breakthrough Therapy Designation for generalized anxiety disorder, has three Phase 3 readouts expected in 2026. The company also dosed its first patient in a Phase 2a study of DT402 in autism spectrum disorder."We are unwavering in our mission to forge a new era of psychiatry by applying scientific rigor to psychedelics," said Rob Barrow, CEO of Definium Therapeutics. "With three Phase 3 readouts expected in 2026, we are uniquely positioned to validate the strength of our science, advance care for patients, and continue delivering long-term value for our shareholders."The three trials include Voyage for generalized anxiety disorder in the second quarter, Emerge for major depressive disorder at mid-year, and Panorama for generalized anxiety disorder in the second half. A fourth Phase 3, Ascend, targeting major depressive disorder, is planned for mid-year initiation. Generalized anxiety disorder and major depressive disorder together affect over 50 million people in the United States. The ticker changed from MNMD to DFTX effective January 13.GH Research (NASDAQ: GHRS) in January announced that the FDA lifted the clinical hold on GH001, its proprietary inhaled mebufotenin (5-MeO-DMT) formulation for treatment-resistant depression, clearing the path for U.S. subject enrollment. The compound's Phase 2b trial met its primary endpoint with a 15.5-point placebo-adjusted MADRS reduction on Day 8 (p
MomsSpaghetti
4月前
AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder
February 26, 2026
PDF Version
EMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profile
EMP-01 demonstrated a clinically meaningful placebo-adjusted least squares mean reduction of 11.85 points on the Liebowitz Social Anxiety Scale (LSAS) at Day 43 (Hedges’ g = 0.45; p-value = 0.036, one-tailed)
EMP-01 demonstrated a robust separation from placebo on the Clinician Global Impression–Improvement (CGI-I) assessment: 49% responders vs. 15% for placebo, corresponding to a Number Needed to Treat (NNT) of 2.95
EMP-01 demonstrated improvements across both Fear and Avoidance sub-domains of the LSAS, including improvement in social avoidance behaviors after two administrations over six weeks, and without adjunctive psychotherapy
More detailed analyses of the data will be described in upcoming scientific venues and will guide subsequent development
Conference call scheduled for 8:00 a.m. ET today, February 26, 2026
https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-positive-topline-results-exploratory-phase
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
ListenToMe
7日前
Tiger Money
2月前
メールアドレスで登録
